Innate Immunotherapeutics Limited (ASX Code:IIL) confirms that the clinical phase of the Phase 2B trial of MIS416 in patients with secondary progressive multiple sclerosis (SPMS) will be completed by the end of April as scheduled.
Innate is conducting an exploratory double blinded, 2:1 randomised, placebo controlled study into the safety and efficacy of the Company's drug candidate MIS416 when administered once weekly over a twelve month period. Ninety three patients with SPMS have been enrolled into the study between late 2014 and April 2016. The final sixteen patients will complete the study over the next eight weeks with the last patient scheduled to complete their last study visit on 19 April.
For further information please download PDF attached:
Download this document
